|
Boehringer Ingelheim's tiotropium shows promising results in patients with …
News-Medical.net Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of tiotropium in asthma. These data were presented at the American Thoracic Society … Phase III results: tiotropium* Respimat® effective in symptomatic asthma … Boehringer Ingelheim reports positive data from symptomatic asthma trials |
View full post on asthma – Google News